CLDN18.2:
Test and interpret with confidence

Help identify a specific subpopulation of patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma to guide treatment approaches.

 

Click on each section below to explore CLDN18.2

Close up of microscope in laboratory setting with overlaid green abstract pattern on dark background
Close up of microscope in laboratory setting with overlaid green abstract pattern on dark background

What is CLDN18.2?

CLDN18.2 is an actionable, predictive biomarker in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.1

Lab technician in blue gloves using forceps to prepare a tissue sample.
Lab technician in blue gloves using forceps to prepare a tissue sample.

Preparing and testing
for CLDN18.2

Learn more about testing for CLDN18.2, including the impact of preanalytical factors on staining, the importance of antibody selection, and the significance of reflexive CLDN18.2 testing upon diagnosis.

Laboratory technician handling tissue cassettes at an embedding workstation.
Laboratory technician handling tissue cassettes at an embedding workstation.

IHC interpretation of CLDN18.2 expression

Accurate CLDN18.2 staining interpretation is critical to support guideline-recommended care.

Two researchers reviewing their findings
Two researchers reviewing their findings

Reporting test results

Review best practices for accurate and consistent reporting of CLDN18.2.

Female doctor typing on a computer
Female doctor typing on a computer

Stain gallery and quiz

Review and test your interpretative pathology skills through matched, consensus-scored, whole-slide images.

Male doctor typing on a computer
Male doctor typing on a computer

CLDN18.2 resources

View additional resources to learn more about how to consistently test, interpret, and report CLDN18.2 in G/GEJ cancer.

Books on bookshelves
Books on bookshelves

FAQs

View a list of frequently asked questions about CLDN18.2 testing in G/GEJ cancer.

Individual typing on a computer
Individual typing on a computer

Reference:

  • 1. Shitara K, Xu RH, Ajani JA, et al. Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer. 2024;27(5):1058-1068.